Interleukin-2 increases the oxidative activity and induces migration of murine polymorphonuclear leukocytes in vivo
Authors:
- 1 January 1990
- journal article
- research article
- Published by Elsevier in International Journal of Immunopharmacology
- Vol. 12 (6) , 605-611
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.Journal of Experimental Medicine, 1989
- A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity.Journal of Experimental Medicine, 1988
- Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytesBiochemical and Biophysical Research Communications, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Recombinant interleukin-2 directly augments the cytotoxicity of human monocytesNature, 1987
- Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells.Journal of Experimental Medicine, 1985
- Site-Specific Mutagenesis of the Human Interleukin-2 Gene: Structure-Function Analysis of the Cysteine ResiduesScience, 1984
- IN VIVO ADMINISTRATION OF INTERLEUKIN-2 ENHANCES SPECIFIC ALLOIMMUNE RESPONSESTransplantation, 1983
- Chemiluminescence by Polymorphonuclear Leukocytes from Patients with Active Bacterial InfectionThe Journal of Infectious Diseases, 1980
- Selective in Vitro Growth of T Lymphocytes from Normal Human Bone MarrowsScience, 1976